克拉生坦联合西洛他唑治疗蛛网膜下腔出血后脑血管痉挛的疗效:回顾性多中心注册研究
本研究基于日本20家机构2023年4月至2024年3月的回顾性多中心注册数据,纳入161例动脉瘤性蛛网膜下腔出血(aSAH)后48小时内行动脉瘤夹闭或栓塞、术前改良Rankin量表(mRS)评分0-2分的患者,比较克拉生坦联合西洛他唑组(94例)与未联用西洛他唑组(67例)的疗效。结果显示两组出院时良好预后(mRS 0-2分)无显著差异,但联合组 delayed cerebral ischemia(DCI)发生率显著更低(0.0% vs 7.5%,p=0.02),其他并发症无显著差异。结论认为联合治疗可能降低DCI发生率,但对功能结局的影响尚不明确。
要点
- 克拉生坦联合西洛他唑可能降低aSAH后DCI发生率(0.0% vs 7.5%,p=0.02)。
- 联合治疗对出院时功能结局(mRS 0-2分)无显著改善。
- 两组其他并发症(脑血管痉挛、肺部并发症、低血压、脑水肿、新发颅内出血)无显著差异。
核心结论
- 克拉生坦联合西洛他唑可能降低aSAH后DCI发生率,但对功能结局的影响尚不明确。
研究设计与样本
- 回顾性多中心注册研究,使用2023年4月至2024年3月日本20家机构的数据。
- 纳入aSAH后48小时内行动脉瘤栓塞或夹闭、术前mRS评分0-2分的患者,排除接受克拉生坦联合法舒地尔者。
- 共纳入161例,其中克拉生坦联合西洛他唑组94例,未联用西洛他唑组67例。
主要发现
- 两组出院时良好预后(mRS 0-2分)无显著差异。
- 联合组不良预后(mRS>2分)有低于非联合组的趋势(11.7% vs 14.9%,OR 0.36,95%CI 0.11-1.2,p=0.095)。
- 联合组DCI发生率显著低于非联合组(0.0% vs 7.5%,p=0.02)。
- 两组在其他并发症(脑血管痉挛、肺部并发症、低血压、脑水肿、新发颅内出血)方面无显著差异。
临床怎么用
- 对于aSAH后接受克拉生坦治疗的患者,联用西洛他唑可能有助于降低DCI风险。
- 联合治疗对功能结局的改善证据尚不充分,需个体化评估。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 样本量较小(161例),统计效能有限。
- 联合组不良预后差异仅为趋势性(p=0.095),未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH) is associated with a poor prognosis. Since 2022, clazosentan has become available for clinical use in Japan and has shown potential in improving clinical outcomes for patients with aSAH. However, whether clazosentan alone is sufficient to achieve optimal results or combination therapy is required remains unclear. In this study, the authors aimed to assess the efficacy of combining clazosentan and cilostazol for treating cerebral vasospasm following aSAH due to a ruptured cerebral aneurysm. METHODS: This retrospective multicenter study was conducted using repository data from April 2023 to March 2024 from across 20 institutes. Patients who underwent coil embolization or surgical clipping within 48 hours of aSAH and had a preoperative modified Rankin Scale (mRS) score of 0-2 were eligible for inclusion in the study. Patients who received clazosentan plus fasudil were excluded. The patients were divided into two groups: those who received clazosentan plus cilostazol (cilostazol combination group) and those who did not receive cilostazol (noncilostazol group). Outcomes were measured based on discharge mRS scores (primary) and complications (secondary), including cerebral vasospasm, delayed cerebral ischemia (DCI), pulmonary complications, hypotension, cerebral edema, and de novo intracranial hemorrhage. RESULTS: In total, 161 patients were included in this study, with 94 and 67 patients in the cilostazol combination and noncilostazol groups, respectively. No significant difference was observed between the two groups in terms of optimal outcomes at discharge (mRS score 0-2). However, the cilostazol combination group tended to experience a lower rate of poor outcomes than the noncilostazol group (11.7% vs 14.9%, respectively, OR 0.36, 95% CI 0.11-1.2, p = 0.095). The incidence rate of DCI was significantly lower in the cilostazol combination group than in the noncilostazol group (0.0% vs 7.5%, p = 0.02). No significant differences were found between the two groups with respect to other complications. CONCLUSIONS: The combination of clazosentan and cilostazol may reduce the incidence of DCI, although its impact on functional outcomes remains unclear. Further research is warranted to explore effective pharmacological strategies for improving the prognosis of aSAH.
引用
- Takeuchi I, Muraoka S, Kinoshita F, et al. Efficacy of combined clazosentan and cilostazol therapy for cerebral vasospasm after subarachnoid hemorrhage: a retrospective multicenter registry study. J Neurosurg. 2025. PMID: 40972040. doi:10.3171/2025.5.JNS243007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。